Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy

Table 1 Alterations of the median blood hormone concentrations at baseline and during therapy

Variable	Baseline	6/8 weeks	12/14 weeks	p value*	Effect size*
Participants, n	28	28	28
LH (U/L)	12 [IQR: 7.8–31] range: 0.8–79	18 [IQR: 10–33] range: 1.7–56	14 [IQR: 5.6–23] range: 0–60	0.72	W = 0.012
FSH (U/L)	22 [IQR: 16–52] range: 2.4–130	33 [IQR: 18–71] range: 5.1–110	33 [IQR: 14–57] range: 3.4–120	0.6	W = 0.018
LH/FSH ratio	0.55 [IQR: 0.43–0.72] range: 0.16–3.9	0.51 [IQR: 0.46–0.68] range: 0.18–1.1	0.51 [IQR: 0.36–0.69] range: 0.056–23	0.65	W = 0.015
Prolactin (µg/L)	8.4 [IQR: 7.2–14] range: 2.8–38	8.7 [IQR: 7.2–12] range: 3.1–40	8.4 [IQR: 6.6–14] range: 0–66	0.94	W = 0.0023
Estrogen (ng/L)	26 [IQR: 0–38] range: 0–62	24 [IQR: 0–34] range: 0–69	28 [IQR: 17–38] range: 0–73	0.41	W = 0.032
Testosterone (µg/L)	2.8 [IQR: 0.13–4.9] range: 0–7.6	2.7 [IQR: 0.18–4.9] range: 0–6.9	1.9 [IQR: 0.14–4.6] range: 0–7	0.75	W = 0.01

ISSN: 2042-6410